BC Extra | Dec 26, 2019
Company News

Dec. 27 Company Quick Takes: Immunomedics, Qiagen, Eisai-Gilead, Melinta, Denovo-Rumpus

FDA again reviewing Immunomedics’ ADC  FDA has accepted a resubmitted BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan to treat third-line metastatic triple-negative breast cancer. The company had received a complete response...
BC Week In Review | Jun 15, 2018
Company News

Denovo gains IP from Stanford to develop lead program for new indication

Denovo Biopharma LLC (San Diego, Calif.) received exclusive, worldwide rights to IP from the Stanford University School of Medicine (Stanford, Calif.) that the biotech said will allow it to develop lead program enzastaurin (DB102) for...
BC Week In Review | Oct 27, 2017
Clinical News

U.S. and China clear Phase III of DB102 to treat DLBCL

Denovo Biopharma LLC (San Diego, Calif.) said FDA and China FDA approved an IND to begin the Phase III ENGINE trial of enzastaurin (DB102) to treat diffuse large B cell lymphoma (DLBCL). The double-blind, placebo-controlled,...
BC Week In Review | Nov 10, 2014
Company News

Eli Lilly, Denovo Biopharma deal

Denovo acquired enzastaurin ( DB102 ) from Eli Lilly. In 2013, Lilly discontinued development of enzastaurin (formerly LY317615 ) after the compound missed the primary endpoint in the Phase III PRELUDE trial to treat relapsed or refractory diffuse...
BC Innovations | Sep 19, 2013
Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Protein kinase Cb (PRKCB) Mouse studies suggest PRKCB inhibitors could help treat MS. PRKCB can induce hyperpermeability of the blood brain...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

Despite one segment that finished the second quarter in the red, all market cap groups are still up for the year. In 2Q13, the sector was led by large caps, which closed up 4%, marking...
BC Week In Review | May 13, 2013
Clinical News

Enzastaurin: Development discontinued

Eli Lilly discontinued development of enzastaurin after top-line data from the double-blind, international Phase III PRELUDE trial in 758 DLBCL patients showed that enzastaurin missed the primary endpoint of improving DFS vs. placebo. Patients received...
BC Extra | May 11, 2013
Clinical News

Lilly discontinues enzastaurin after Phase III miss

Eli Lilly and Co. (NYSE:LLY) discontinued development of enzastaurin (LY31765) after top-line data showed daily enzastaurin missed the primary endpoint of improving disease-free survival (DFS) vs. placebo in the Phase III PRELUDE trial to treat...
BC Innovations | Sep 20, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Sarcoma Protein kinase Cb (PRKCB) In vitro and mouse studies suggest PRKCB inhibitors could help treat Ewing's sarcoma. PRKCB was overexpressed in primary Ewing's sarcomas...
BioCentury | Oct 13, 2008
Strategy

Lilly's oncology pipeline

Lilly's oncology pipeline Compound [partner] Description Lead indication Status Enzastaurin Synthetic protein kinase C (PKC) beta inhibitor Relapsed or refractory diffuse large B cell lymphoma (DLBCL) Ph III IMC-1121B Human mAb against vascular endothelial growth...
Items per page:
1 - 10 of 23